Group items tagged

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

Community pharmacies are well placed to play a role in preventing deaths from cardiovascular disease (CVD) said Director of NHS Services. The recent analysis by the British Heart Foundation (BHF) revealed that nearly 100,000 more people with cardiovascular disease than expected have died since the start of the pandemic in England. Latest figures show that the number of people waiting for time-sensitive cardiac care was at a record high of nearly 390,000 at the end of April in England. Average ambulance response times for heart attacks and strokes have consistently been above 30 minutes since the beginning of 2022, and in December 2022 they even breached 90 minutes. The target is 18 minutes, though the Government has set a new average target of 30 minutes over 2023/24. Director of NHS Services, Alastair Buxton, said: "It is concerning to hear that there have been tens of thousands of preventable deaths from cardiovascular disease (CVD) since the start of the COVID-19 pandemic. We share BHF's desire to see more action on preventing the causes of CVD and, subject to appropriate funding being in place, community pharmacy teams are well placed to play a role in this.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

Community pharmacies will be able to deliver approximately 15 million blood pressure screenings by 2026, revealed the Company Chemists' Association (CCA)'s new research. This will also prevent 15,000 people from suffering heart attacks or strokes. CCA has called the Government to take up their offer and commission pharmacies as the first port of call for cardiovascular care. "Thousands of lives can be saved with ambitious commissioning and the investment to match," said CCA. There is an opportunity to use the expertise of community pharmacy to go further and provide the care these newly identified patients' need. To do this the sector needs funding and workforce. The association said: "Community pharmacy is under great financial pressure, suffering a real term funding cut of over 30% over 8 years. With funding, the sector can transform to deliver this critical need for patients. Whilst there are plans to train Independent Prescribers (IPs), there are no clear roles for them to use these skills. There is a need to accelerate training plans to allow pharmacists to deliver the service described here and play their part in CVD management."

Cardiovascular diseases (CVDs) are the types of diseases that affect heart and blood vessels, causing heart attacks, stroke, congenital heart disease, and peripheral artery disease. Tobacco use, unhealthy diet, alcohol, and physical inactivity trigger CVDs. Here's all you need to know about CVDs.

Good morning friends,starting from this post onwards i will try to explain some changes the human body undergoes during pregnancy.Today I'll make an attempt to explain the cardiovascular changes in pregnancy[heart & the circulatory system]

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

As Know Your Numbers! Week (2-8 September) kicks off, the NHS England is encouraging people in the East Midlands to get their blood pressure checked to prevent heart attacks and strokes. The residents can get their blood pressure checked at several places, including their local pharmacies. The initiative, part of a global campaign, highlights the crucial role of monitoring blood pressure, especially for those aged 40 and over. It is recommended that all adults aged 40 or over have their blood pressure tested at least every five years. High blood pressure or hypertension affects about a third of adults in the UK and is a major risk factor for cardiovascular disease (CVD), which is one of the leading causes of death in England. This condition often has no noticeable symptoms, but if untreated, it can result in serious health problems such as heart attacks and strokes. Local pharmacies play a crucial role in this health campaign, enabling individuals to monitor their risk of cardiovascular disease without needing an appointment. The NHS community pharmacy blood pressure check service has delivered more than a million checks nationally in the past year.

The drug Multaq, from Sanofi-Aventis, is used to treat cardiac arrhythmias, however the FDA has issued a warning today stating that in further trials it has shown a serious risk of cardiovascular problems, including death.

Management and prevention of cardiovascular diseases involves a commitment to physical activity, diet, heart health, medication adherence, and self-monitoring. Keeping all the activities at check is a daunting task and requires a great deal of adherence to a healthy routine.

We take pleasure to announce First Edition of "World Congress on Cardiovascular Diseases" which will take place during March 23-24, 2020 at UK in beautiful city London.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

In partnership with the pharmaceutical company Boehringer Ingelheim, Leeds Teaching Hospitals Trust (LTHT) has recently established an innovative cardiometabolic clinic. The clinic focuses on reducing cardiovascular risk in people with diabetes who have recently been discharged from LTHT following a heart attack. It is delivered jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. This is a patient-centred approach to reducing that risk, with pharmacist-delivered clinics scheduled for six to eight weeks after the heart attack. Stephen Wheatcroft, Professor of Cardiometabolic Medicine and Consultant Cardiologist at LTHT, said: "This is an exciting and innovative development, one of the first in the country. Previously, Type 2 diabetic patients presenting with heart issues would have been treated by two separate specialty teams. This is the first time there has been a specific clinic combining the cardiac and diabetes team working together. "We aim to reduce the risk for patients, with earlier multidisciplinary hospital care, to help discharged patients achieve better diabetes control, through improved medication support and optimisation, reducing the need for further treatment and future hospital stays. Overall, it will mean a better patient experience, with improved monitoring and information about treatment options, along with a reduction in waiting times for review in a specialist clinic."

Getting a good night's sleep is crucial for maintaining both physical and mental health, alongside a balanced diet and regular exercise. Chronic sleep deprivation has been linked to an increased risk of serious conditions like diabetes and heart disease. So, if you're sleep deprived during weekdays, try to make up for it by getting extra sleep on weekends. A new study has revealed catching up with compensatory sleep on weekends can significantly reduce the risk of heart disease. The study conducted by the National Centre for Cardiovascular Disease in Beijing, China, found that individuals who catch up on sleep over the weekend may lower their risk of heart disease by one-fifth. Study co-author Yanjun Song from the State Key Laboratory of Infectious Disease at Fuwai Hospital emphasised that the benefit of compensatory sleep was even more pronounced among individuals who regularly experience inadequate sleep on weekdays. The researchers used data from 90,903 subjects involved in the UK Biobank project to evaluate the relationship between compensated weekend sleep and heart disease. More than 21 per cent of the participants were identified as sleep-deprived - defined as getting less than seven hours of sleep per night.

Cardiovascular disease is the number one cause of death and number one cause of hospitalization in developed countries. Statin drugs are a common drug of choice in the prevention (lower cholesterol) and treatment of heart disease. The research is quite compelling showing the benefits of statin therapy. However does everyone need a statin?

Developing holistic fitness means you will be fit for anything that life throws at you. You'll have the strength to overcome almost any physically demanding challenge plus the cardiovascular fitness to ensure your heart, lungs and circulatory system are fit and healthy.

Running and Jogging: Health Benefits. Running is one of the best cardiovascular workouts. It makes the muscles strong and tones them as well.Regular jogging

There is an increased importance of exercise and healthy diet. However, proper amount of rest is also vital for maintaining good health. There should be a proper balance between stretching, cardiovascular activities, and weight training. Along with all this, proper workout is needed to obtain high levels of fitness. Proper rest is especially important for people who try to increase their weight and mass of muscles. HGH Human Growth Hormone is responsible for the growth of muscles.